If your organization’s cardiometabolic health strategy begins and ends with GLP-1 coverage, you don’t really have a strategy. You have a pharmacy decision masquerading as population health. The post The cost of discontinued care: Why GLP-1 coverage fails without clinical continuity appeared first on Vida .